

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				RU-0130
INTERNATIONAL APPLICATION NO. PCT/US00/03878		INTERNATIONAL FILING DATE 15 February 2000		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <b>09/913435</b>
TITLE OF INVENTION Novel Redox Clamping Agents and Uses Thereof		PRIORITY DATE CLAIMED 16 February 1999		
APPLICANT(S) FOR DO/EO/US YURKOW, Edward J. et al.				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2))        a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).        b. <input type="checkbox"/> has been communicated by the International Bureau.        c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).        a. <input type="checkbox"/> is attached hereto.        b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))        a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).        b. <input type="checkbox"/> have been communicated by the International Bureau.        c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.        d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). - <b>unexecuted</b></p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</p> <p>11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</p> <p>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</p>				
Items 13 to 20 below concern document(s) or information included:				
<p>13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in cc</p> <p>15. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment.</p> <p>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</p> <p>17. <input type="checkbox"/> A substitute specification.</p> <p>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with</p> <p>20. <input type="checkbox"/> A second copy of the published international application under 35 U</p> <p>21. <input type="checkbox"/> A second copy of the English language translation of the international application.</p> <p>22. <input type="checkbox"/> Certificate of Mailing by Express Mail</p> <p>23. <input checked="" type="checkbox"/> Other items or information:        1) Courtesy copy of International Application        2) Written Opinion        3) Return post card</p>				
<p>"Express Mail" Label No. <b>EL750774435US</b>        Date of Deposit <b>August 14, 2001</b></p> <p>I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.</p> <p>By <u>Deborah Ehret</u>        Typed Name: Deborah Ehret</p>				

APPLICATION NO. (IF KNOWN, SEE 37 CFR) <b>09/913435</b>	INTERNATIONAL APPLICATION NO. <b>PCT/US00/03878</b>	ATTORNEY'S DOCKET NUMBER <b>RU-0130</b>
--	--	--

24. The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....	\$1000.00
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....	\$860.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	\$710.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....	\$690.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....	\$100.00

**CALCULATIONS PTO USE ONLY**

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

**\$860.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).

20  30

**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	5 - 20 =	0	x \$18.00	<b>\$0.00</b>
Independent claims	5 - 3 =	2	x \$80.00	<b>\$160.00</b>

Multiple Dependent Claims (check if applicable).

**TOTAL OF ABOVE CALCULATIONS = \$1,020.00**

Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

**\$510.00**

**SUBTOTAL = \$510.00**

Processing fee of **\$130.00** for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).

20  30

**\$0.00**

**TOTAL NATIONAL FEE = \$510.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

**\$0.00**

**TOTAL FEES ENCLOSED = \$510.00**

**Rutgers, the State University is entitled to small entity status. It is a non-profit organization.**


Amount to be: refunded	\$
charged	\$

- A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.
- Please charge my Deposit Account No. 50-1619 in the amount of \$510.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1619 A duplicate copy of this sheet is enclosed.
- Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Reg. No. 32,257  
Kathleen A. Tyrrell, Reg. No. 38,350  
Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053  
Telephone: (856) 810-1515  
Facsimile: (856) 810-1454

  
SIGNATURE

**Kathleen A. Tyrrell**

NAME

38,350

REGISTRATION NUMBER

August 14, 2001

DATE

NOVEL REDOX CLAMPING AGENTS AND USES THEREOFField of the Invention

The present invention relates to a novel class of chemosensitizing agents that function by "locking" or 5 "clamping" cells at a selected cellular redox state. The selected cellular redox state in which the cells are maintained by these agents is optimal for the cellular processes mediating apoptosis, normal cellular growth control and differentiation. Accordingly, these agents are useful in 10 sensitizing cells to the effects of therapeutics including, but not limited to antineoplastics such as butyrate and butyrate analogs.

Background of the Invention

It is becoming increasingly clear that apoptosis plays 15 an important role in the promotional phase of cancer development. Suppression of apoptosis has been suggested to be a universal property of cancer promoters while a number of agents which upregulate apoptosis in pre-neoplastic and neoplastic cells have been suggested to be useful 20 therapeutically in the treatment of neoplasia (McCarty, M.F., *Med. Hypotheses*, 1998, 50(5):423-33).

For example, butyrate which has been shown to induce apoptosis in various types of cancer is currently being considered as a potential cancer chemotherapeutic agent. 25 The mechanism by which butyrate functions to induce apoptosis

- 2 -

and alter the growth and differentiation state of cancer cells is not known. However, treatment with butyrate has been shown to decrease cellular levels of reduced glutathione (GSH), a major determinant of cellular redox status (Benard, O., and 5 Balasubaramanian, K.A., *Mol. Cell Biochem.*, 1997, 170:109-114). This butyrate-induced decrease in cellular GSH levels correlates with the differentiation and apoptosis of cultured cancer cells. Furthermore, agents known to modulate (i.e., decrease) cellular GSH levels also enhance the differentiating 10 effects of butyrate in short-term *in vitro* assays (Benard, O., and Balasubaramanian, K.A., *Mol. Cell Biochem.*, 1997, 170:109-114). Butyrate derivatives have also been shown to exhibit radiosensitizing properties (Chung et al., *Radiat. Res.*, 1998, 149(2): 187-194). Generally, agents that increase the 15 sensitivity of cells to radiation do so by decreasing the natural ability of cells to oppose radiation-induced oxidative stress. Agents that decrease cellular glutathione or inhibit the action/expression of antioxidant enzymes/proteins sensitize cells to the effects of radiation. Therefore, the 20 radiosensitizing effects of butyrate reflect the ability of this agent to modify the redox capacity of cells.

However, while butyrate decreases cellular GSH, this short-chain fatty acid also induces genes that oppose this change in the cellular redox status. Specifically, butyrate 25 treatment is associated with the elevated expression of the potent antioxidant and metal-chelating protein, metallothionein (MT) (Liu et al., *In Vitro Cell Dev. Biol.*, 1992, 28A:320-326). Elevations in MT and other antioxidant-generating systems can oppose the redox conditions initially 30 attained by the effect of butyrate on GSH levels. The disruption of the cellular redox state by the effect of butyrate on cellular GSH levels, causes the cells to readjust the redox status by the modulation of redundant elements of redox control. Readjustments of the redox state in this 35 manner can oppose the therapeutic action of butyrate. For

- 3 -

example, there is evidence that butyrate-induced MT expression can, in part, oppose the redox conditions initially attained by the effect of butyrate on GSH levels. There is evidence suggesting that butyrate-induced MT expression can, in part, 5 explain the gradual development of resistance to butyrate following prolonged treatment. Further, an over-expression of the antioxidant MT has been disclosed to compensate for low cellular GSH levels (Miura et al., *Life Sci.*, 1997 60(21):301-309).

10 A novel class of agents has now been identified with the ability to maintain cells in a selected redox state. These agents do not permit the cell to successfully compensate for treatment-induced alterations in cellular redox status. For this reason, these agents are useful in enhancing the 15 therapeutic activity of chemotherapeutic agents (such as butyrate) that is dependent upon the redox state of the cell. These agents are also useful in controlling hyperproliferation of cells and conditions associated with abnormal fluctuations in the redox state of cells.

20

#### Summary of the Invention

A novel class of compounds, referred to herein as redox clamping agents, has now been identified which comprise thiol-containing molecules with the ability to reduce specific 25 cellular oxidizing systems and/or molecules while maintaining other redox active systems in the oxidized state so that a cell is maintained in a selected redox state.

Accordingly, an object of the present invention is to provide a method of maintaining cells in a selected redox state which comprises contacting the cells with a redox clamping agent which maintains the cells in a selected redox state.

Another object of the present invention is to provide a method of sensitizing selected cells to a chemotherapeutic 35 agent known to induce a stress response in cells which

- 4 -

comprises contacting the selected cells with the chemotherapeutic agent in combination with a redox clamping agent.

Another object of the present invention is to provide 5 a method of treating cancer in a patient which comprises administering to the patient a chemotherapeutic agent known to induce a stress response in cancer cells in combination with a redox clamping agent.

Another object of the present invention is to provide 10 a method of inhibiting hyperproliferation of cells which comprises contacting the cells with a redox clamping agent.

Yet another object of the present invention is to provide a method of stabilizing the redox state of cells with abnormal fluctuations in their redox states which comprises 15 contacting the cells with a redox clamping agent.

#### Detailed Description of the Invention

The cellular redox status (i.e., the capacity of cells to conduct oxidation/reduction reactions and to maintain the oxidized or reduced state of thiols) is an aspect of the 20 intracellular environment that has a controlling influence on numerous cellular processes (Sun, Y., and Oberly, L.W., *Free Rad. Biol. & Med.*, 1996, 21(3):335-348; Monteiro, H.P., and Stern, A., *Free Rad. & Biol. & Med.*, 1996, 21(3): 323-333). Redox sensitive pathways extend from simple metabolism to 25 critical cell signal transduction cascades controlling gene expression, growth, differentiation and apoptosis.

A novel class of compounds has now been identified which are capable of locking or clamping cells in a specific redox state. These compounds, referred to herein as "redox clamping 30 agents" comprise thiol (sulphydryl)-containing molecules with specific chemical properties which include the ability to reduce specific cellular oxidizing systems and/or molecules while maintaining other redox active systems in the oxidized state. This is a major differentiating aspect between these

- 5 -

agents and other agents that affect cellular redox status. These redox clamping agents are distinct from antioxidants since antioxidants permit major swings in the redox status and can only prevent the development of a pro-oxidizing state.

5        The function of redox clamping agents is not solely to deplete cellular levels of antioxidants, thiols, or antioxidant proteins/enzymes (i.e., metallothionein, glutathione reductase, etc.). Rather, the reason for the application of redox clamping agents to living systems is to  
10      adjust and maintain the relative amounts of (redox defining) cellular constituents such that a specific redox condition is sustained. In this respect, redox clamping agents are distinct from agents that simply deplete cellular GSH or decrease the expression or cellular levels of antioxidant  
15      proteins or enzymes. Unlike redox clamping agents, such agents do no oppose the readjustments of the redox state following treatment.

20      The ability of these agents to clamp or fix cells in a selected redox state renders these agents useful in a variety of therapeutic applications. Redox clamping agents can be used in combination with numerous chemotherapies for the treatment of cancer and pre-neoplastic disease as well as other medical conditions characterized by hyperproliferation of cells or abnormal cellular redox states.

25      For example, butyrate shows promise for the clinical management of prostate cancer and benign prostate conditions. However, the serum levels required to achieve favorable results are high (> 5 mM) and difficult to maintain (Newmark, H.L., and Young, C.W., *J. Cell Biochem. Suppl.*, 1995, 22:247-  
30      253). Furthermore, butyrate resistant cells can arise from tumors following prolonged treatment with this agent (Ho et al., *J. Cell Physiol.*, 1994, 160(2):213-226). Thus, there is a need for agents that can chemosensitize cells to butyrate and prevent the development of butyrate resistance. These  
35      agents would serve to lower the serum levels of butyrate

- 6 -

required for anti-tumor activity and extend the therapeutic period.

It is believed that the anti-tumor effects of butyrate are sensitive to and/or dependent upon cellular redox conditions. It has now been demonstrated that redox clamping agents of the present invention work to enhance the ability of butyrate to inhibit growth and induce the differentiation and apoptosis of established prostate cancer cell lines (i.e., LNCaP and PC-3).

Thirty redox modulating agents or cell culture conditions were tested for their ability to influence butyrate-mediated apoptosis. In addition, the effect of some of these agents or conditions on the ability of butyrate to decrease cellular GSH levels and increase cellular MT levels was examined. The focus of these studies was to identify agents that permit/promote the GSH-lowering effects of butyrate and oppose treatment-induced readjustment of redox status by the cell. Included in this screen were agents that are classical redox modulating agents. Other agents were chosen based on their ability to alter cellular redox states as determined in preliminary studies. A partial list of the tested agents is provided in the following table.

	Group 1 Classical Redox Modulators Tested	Group 2 Additional Redox Modulators Tested	Group 3 Butyrate- sensitizing Redox Clamping Agents
25	Buthionine sulfoximine*	Cysteamine (2-aminoethanethiol)	DMSA (meso-2,3- dimercaptosuccinic acid)
30	Methionine sulfoximine	Lipoic acid (a.k.a. thioctic acid)	MESNA (2- mercaptoethane- sulfonic acid)
	Ethacrynic acid (GST Inhibitor)	PDTC (pyrrolidine dithiocarbamate)	Reduced (i.e. 1/4) cystine in medium
	NAC (N-acetyl cysteine)	2-Mercapto-1- propanesulfonic acid	

Acivacin*	2,3-Dimercaptor-1-propane-sulfonic acid*	
Propargyl-glycine*	DTT (dithiothreitol)	
Ascorbic acid*	Glutathione ester	

5 Although many of the agents listed above were found to enhance butyrate-induced apoptosis (\*), extended treatment with some of the compounds resulted in cells having elevated levels of GSH and/or MT. Further, many of these agents were found to be toxic to cells while others inhibited the ability of  
10 butyrate to induce apoptosis in LNCaP cells. However, two compounds were identified that functioned in combination with butyrate to induce apoptosis in LNCaP and PC-3 cells.

One of the compounds found to function in combination with butyrate was meso-2, 3-dimercaptosuccinic acid (DMSA).  
15 This agent is currently used in the clinic to lower the body burden of toxic, heavy metals following inadvertent human exposure (Miller, A.L., *Altern. Med. Rev.*, 1998, 3(3):199-207). DMSA functions in this capacity by chelating heavy metals that are deposited within tissues and facilitating  
20 their excretion. Although DMSA alone was found to be a weak inducer of metallothionein (MT) in these studies, LNCaP cells treated with combinations of DMSA and butyrate exhibited levels of MT that were 75% lower than cells treated with butyrate alone. Therefore, DMSA attenuates the ability of  
25 butyrate to elevate cellular MT levels. The half-life of the MT protein is dependent on the presence of transitional metal ions such as zinc. For example, it has been shown that MT-metal complexes exhibit a resistance to protease digestion (McKim et al., *Toxicol. Appl. Pharmacol.*, 1992, 116(19):117-124). Therefore, DMSA may function to decrease butyrate-induced elevations in cellular MT levels by sequestering the metal ions needed to stabilize the MT protein.

- 8 -

The second compound found to function in combination with butyrate to induce apoptosis was 2-mercaptopethanesulfonic acid (MESNA). This finding was unexpected since MESNA is used clinically as a uroprotectant with putative antioxidant properties (Holooye et al., *Am. J. Clin. Oncol.*, 1990, 13(2):148-155). However, while MESNA treatment alone was found to have minimal effect on apoptosis, coadministration of MESNA markedly enhanced butyrate-induced apoptosis. Interestingly, this agent completely inhibits butyrate-induced MT expression and slightly enhances butyrate-induced decreases in cellular GSH.

The combination of all three agents was found to be the most effective at promoting apoptosis in the LNCaP human prostate cancer cell line.

Based on these experiments, both DMSA and MESNA have been identified as members of the class of redox clamping agents of the present invention since both compounds appear to force butyrate-treated cells to maintain a specific redox state that is apparently optimal for promoting differentiation and apoptosis. Results from these *in vitro* experiments will be confirmed *in vivo* in an established mouse model for prostate cancer. It has been demonstrated that established human prostate cell lines when grafted into nude mice will achieve and maintain a redox state that closely resembles that of *in situ* prostate cancer cells (Canada et al., *Biochem. Pharmacol.*, 1996, 51:87-90). Accordingly, pre-clinical evaluation of these agents using the nude mouse model of human prostate cancer will be performed.

It is expected that the combination of butyrate/DMSA/MESNA will inhibit the growth of human prostate tumors in the nude mouse model relative to other test groups. Other combinations (i.e., butyrate/DMSA, butyrate/MESNA) are also expected to be a more effective therapy than butyrate alone. Examination of the tumors from butyrate-treated animals is expected to show an increase in PSA mRNA, a

decrease in Bcl-2/Bax ratio and a decreased proliferation of cells relative to tumors from untreated animals. These indicators, which reflect increased differentiation and decreased tumor growth, should improve in tumors from animals 5 treated with the various combination therapies. Furthermore, these indicators should correlate with decreased cellular levels of GSH and MT. For example, tumors with the highest PSA mRNA levels, lowest Bcl-2/Bax ratio and lowest proliferation indexes should contain levels of cellular GSH, 10 MT and other redox-defining molecules that fall within a specific range and that define a specific redox state. Histologic examination should find less mitotic figures, normal chromatin condensation and characteristics of differentiation of tumors isolated from animals treated with 15 combinations relative to controls and animals treated with butyrate alone. Accordingly, not only will these studies provide insight into the manner by which DMSA and MESNA function and interact to enhance the anti-tumor activity of butyrate, but they will also provide a means to identify and 20 develop additional redox clamping agents that function in a similar manner. Further, results from *in vivo* studies, along with data from *in vitro* experiments described herein, will provide insight into dosage regimens, effective concentrations, toxicity and the therapeutic potential of the 25 butyrate chemosensitizers for use in the design of human clinical trials.

Thus, as demonstrated herein, in one embodiment, the redox clamping agents of the present invention are useful in the treatment of neoplasia in conjunction with a 30 chemotherapeutic agent known to induce a stress response in cancer cells. An example of such a chemotherapeutic agent is butyrate for the treatment of prostate cancer. Cancer cells respond to the stress induced by the chemotherapeutic agent by upregulating various cellular processes that oppose the 35 stress. The drug-induced stress response makes the cancer

- 10 -

cells that survive the initial stress more robust thereby enabling them to grow in a more uncontrolled manner and to become resistant to subsequent treatment with the same or different chemotherapeutic agents. In the present invention, 5 however, the redox clamping agent is co-administered with the chemotherapeutic agent known to induce a stress response in cancer cells. The redox clamping agent is administered in combination, either prior to and/or during and/or after the administration of the chemotherapeutic agent. The redox 10 clamping agent functions to oppose the treatment-associated stress response of the cancer cells, by adjusting the redox state of these cells to a region where cell death mechanisms remain active thereby making the cancer cells more sensitive to killing by the chemotherapeutic agent, increasing the 15 efficacy of the chemotherapeutic agent and inhibiting the development of resistance.

In another embodiment, the redox clamping agents are used as antiproliferative agent to be administered before an angioplasty procedure. Angioplasty is a medical procedure 20 that is conducted to open an obstructed blood vessel. This permits an increased blood flow to oxygen-deprived tissue. However, the physical trauma inflicted on the internal walls of the vessel during angioplasty, as well as the abrupt changes in the oxygen concentration in the vessel following 25 this procedure, induces a transient proliferation of the cells constituting the vessel. This proliferative response can be significant, resulting in a post-procedure thickening of the vessel and decreased blood flow. This proliferative response makes angioplasty procedures less effective. Redox clamping 30 agents can be administered prior to and/or during and/or after and angioplasty procedure. These agents induce a redox state of the blood vessel cells that is not consistent with proliferation thereby minimizing the post-procedure proliferation of cells and making the angioplasty procedure 35 more effective.

- 11 -

The redox clamping agents can also be used to treat hyperproliferative conditions of the skin. An increased proliferation and/or altered differentiation of epidermal cells in various skin conditions (i.e., psoriasis) is 5 associated with major alterations in the redox state of the cells. Similarly, elevated cellular levels of the antioxidant glutathione is observed in skin cells following exposure to sunlight (UV light). This alteration in the redox state is a major promotor of cell proliferation in the skin. Redox 10 clamping agents taken orally or included in a topical ointment lessen cell proliferation and normalize the differentiative process.

In yet another embodiment, these redox clamping agents are used for the treatment of Type II (adult onset) diabetes. 15 In Type II diabetes, the cellular process of basal and insulin induced uptake of glucose from the serum is altered. Glucose uptake by cells is mediated by glucose transporters. In diabetic individuals the expression/function of specific types of glucose transporters is decreased. This contributes to the 20 inability of individuals suffering from diabetes to clear serum glucose levels after and between meals. The expression of these transporters is known to be uniquely affected by the redox state of the cells. Dramatic fluctuations in the redox state of tissue of diabetics (due to diminished glucose uptake 25 and utilization) tend to down-regulate the expression and function of the glucose transporters. Such a deficit exacerbates the diabetic condition and promotes elevations in serum glucose. Treatment of the Type II diabetic with a redox clamping agent of the present invention stabilizes the redox 30 state of the cells and normalizes glucose transporter expression/function. This treatment permits individuals suffering from diabetes to more easily manage the disease by normalizing serum glucose levels, thereby slowing progression of this disease.

- 12 -

The following nonlimiting examples are provided to further illustrate the present invention

#### EXAMPLES

**Example 1: Effect of agents/combinations on apoptosis of  
5 LNCaP cells**

LNCaP cells were treated with the agents (alone or in combination) for 48 hours. In these studies, the concentrations used were: MESNA, 50  $\mu$ M; DMSA, 50  $\mu$ M; butyrate, 5 mM. The cells were then harvested and the percentage of 10 apoptotic cells appearing in the sub-diploid peak was determined flow cytometrically.

**Example 2: Effect of agents on cellular reduced glutathione  
(GSH) levels**

Species-specific limitations of the method of GSH 15 determination precluded the use of human LNCaP cells for these studies as the method of GSH detection depends on an isoform of glutathione-S-transferase that is not prevalent in human cells to conjugate the dye to GSH resulting in a fluorescent product. Therefore, the effect of butyrate, MESNA and DMSA 20 on cellular GSH levels was investigated using the H4 rat hepatoma cell line. The GSH-specific fluorescence of butyrate-treated cells was found to be lower than control. Furthermore, DMSA and MESNA treatment decreased basal GSH 25 levels, while other redox modulating agents (i.e., lipoic acid) increased cellular GSH levels. This is of interest since DMSA and MESNA enhanced butyrate-induced apoptosis while lipoic acid was found to be a potent inhibitor. In additional studies, a different cytometry-based method will be employed 30 to determine the cellular levels of reduced glutathione in the human prostate tumor cells. An HPLC-based method will also be used to quantify both reduced and oxidized glutathione.

**Example 3: Effects of MESNA on cellular MT levels**

LNCaP cells were treated as described in Example 1. However, the cells were harvested at the 24 hour time period. The cells were then fixed (paraformaldehyde), stained with a 5 metallothionein-specific (fluorescence-conjugated) antibody and analyzed flow cytometrically. These data indicate that both DMSA and MESNA can inhibit butyrate-induced increase in cellular MT levels. This observation is consistent with the characterization of DMSA and MESNA as redox clamping agents: 10 they appear to oppose the attempt of butyrate-treated cells to become pro-reducing by inhibiting the expressing of antioxidant proteins such as MT while maintaining/enhancing the low GSH levels induced by butyrate.

**Example 4: In vivo model for prostate cancer**

15 The animal model that will be used to test the effect of butyrate combination therapies on human prostate cancer involves injecting (s.c./flank) male athymic (nude) mice with human prostate cancer cells (LNCaP) as described by Raffo et al., *Cancer Res.*, 1995, 55:4438-4445. This method has been 20 shown to yield 100% prostate tumor establishment at the site of injection in approximately 3 weeks. Following a brief (4 day) post-injection period, the mice will be randomly assigned to a treatment group (see Table 2) where they will receive treatment with one or more of the described agents. 25 Approximately forty (40) days post-injection, tumor development will be measured (13) and the tumors will be excised and processed to characterize the effect of the therapeutic combinations on various aspects of tumor growth and differentiation (see Table 2).

30 It is estimated that at least 15 mice/group will be used in the study in accordance with principals set forth by Steel and Torri (1980, *Principals and Procedures of Statistics: A Biometrical Approach*. New York:McGraw-Hill Book Company, Inc). Such estimates assume a pooled standard deviation of tumor

- 14 -

volume of 0.8 and the minimal expected difference between control and test groups of 40%.

**Example 5: Administration of therapeutic agents to mice**

5 DMSA and MESNA will be administered to the mice orally in the drinking water. The pharmacokinetics of oral DMSA and MESNA have been extensively characterized in humans (Aposhian, H.V., and Aposhian, M.M., *Annu. Rev. Pharmacol. Toxicol.*, 1990, 30:279-306; and James et al., *Br. J. Clin. Pharmacol.*, 10 1987, 23(5):561-568). Stability studies indicate that both DMSA and MESNA are stable in simple liquid and solid preparations. Two dosage levels for DMSA and MESNA (i.e., low and high) will be used. The "low dose" will be determined by extrapolation using effective doses in humans. The "high 15 dose" will be threefold higher than the "low dose". Butyrate will be administered to specific dosage groups in the form of the orally active prodrug, tributyrin. Pharmacokinetic data indicate that an oral dose of 5-10 g tributyrin/Kg will result in peak plasma butyrate levels of 1-2 mM (Yuan et al., *Proc. 20 Annu. Meet. Am. Assoc. Cancer Res.*, 1994, 35:A2556). This serum concentration range has been shown to significantly reduce LNCaP tumor growth in nude mice treated with another butyrate prodrug, isobutyramide (Gleave et al., *J. Cell. Biochem.*, 1998, 69(3):271-281.). Food/water intake of the 25 mice will be monitored. If intake varies significantly in any treatment group relative to control or other test groups then paired feeding may be implemented. The fourteen proposed treatment groups are listed in the table below.

Table 2:

Treatment Groups (>15 mice/group)	
Control	Tributyrin (TB)
5 DMSA (low)	DMSA (low) + TB
DMSA (high)	DMSA (high) + TB
MESNA (low)	MESNA (low) + TB
MESNA (high)	MESNA (high) + TB
DMPS + MESNA (low/low)	DMPS + MESNA (low/low) + TB
10 DMPS + MESNA (high/high)	DMPS + MESNA (high/high) + TB

**Example 6: Tumor processing**

Tumor volume will be calculated using standard methods and the tumors will be excised. Pieces of the tumors will be extracted for Western or Northern blot analysis. For flow 15 cytometric analysis, a single cell suspension will be generated from pieces of the tumors using Protease XIV according to established protocols. Various aspects of these cells (i.e., GSH, MT, proliferation index, etc.) will be determined as described in the following examples. In 20 addition, sections of tumor will be preserved and processed for histologic examination. The kidneys and liver from each animal will be preserved for determining treatment-associated organ pathology. Other organs will be preserved and examined if indicators of specific toxicity are observed or suspected.

**25 Example 7: Human prostate cancer cell lines**

The human prostate cancer cell line, LNCaP, will be used in these animal studies. This cell line is an androgen-sensitive prostate cancer cell line that has been used extensively in animal models of human prostate cancer. 30 However, once optimal doses and combinations have been determined for the LNCaP tumors, additional studies in other tumor model systems can be conducted. Since the LNCaP cell

line has been extensively characterized, standard biomarkers reflecting aspects of growth, apoptosis and differentiation have been determined. These biomarkers will be used in this study to determine the anti-tumor effects of the therapeutic 5 combinations, to gain insight into the mechanisms by which DMSA and MESNA function to enhance the effect of butyrate, and to identify additional redox clamping agents.

**Example 8: Effect of the therapeutic combinations on  
10 apoptosis of LNCaP tumors.**

Apoptosis of LNCaP cells, as well as butyrate-induced apoptosis of other cell types, is associated with alterations in the ratio of Bcl-2, Bcl-X and Bax. This mechanism of apoptosis is in contrast to apoptotic processes involving the 15 altered (decreased) expression/function of p53. By measuring the relative quantities of the Bcl-2 family of proteins in the cells of control and treated tumors using standard Western blotting techniques, the ability of the therapeutic combinations to affect mechanisms of apoptosis can be 20 characterized. The expression of other relevant cellular proteins which mediate/reflect or inhibit apoptotic processes and cell cycle arrest (i.e., p53, p21/waf1, p27Kip1, etc.) can also be characterized by either Western or Northern blot analysis to address unexpected treatment-associated phenomena. 25 Detection/quantitation of these proteins or mRNAs are determined using standardized techniques. The percentage of apoptotic cells in tumors from various treatment groups will be determined flow cytometrically using the standard TUNEL assay. For some tumors, the TUNEL assay will be performed 30 using tissue sections.

**Example 9: Effect of the therapeutic combinations on  
differentiation of LNCaP tumors.**

A differentiation marker known as PSA (prostate-specific antigen) has been characterized for the LNCaP cell line.

- 17 -

Increased expression of this protein has been associated with an increase in the differentiation state of this cell line as well as other human prostate cell lines and actual prostate tumors (Gleave et al., *J. Cell. Biochem.*, 1998, 69(3):271-5 281.). The expression of PSA mRNA in LNCaP tumors will be determined in this study by conventional Northern blot analysis. This information will be used to determine the effect of the treatment on the differentiation state of the human tumor.

10 **Example 10: Effect of the therapeutic combinations on proliferation of LNCaP tumors**

Several hours prior to sacrifice, some mice in each treatment group will be injected with bromodeoxyuridine (BrdU). Incorporation of this thymidine analog into the DNA 15 of proliferating cells permits determination of the proliferation index of the tumor flow cytometrically. Human tumor cells can be resolved from contaminating mouse cells cytometrically, since the DNA-specific dye (i.e., propidium iodide) which is used in the assay, stains cells on the basis 20 of total DNA content (human cells have significantly more genomic DNA than mouse cells). A decrease in the percentage of cells incorporating BrdU in tumors from mice receiving a specific combination of agents will be interpreted as a treatment-associated inhibition of tumor growth. These 25 findings will be associated to other characteristics of the tumor (i.e., size/volume, expression of differentiation markers, etc).

**Example 11: Effect of the therapeutic combinations on the redox status of LNCaP tumors**

30 Determinants of differentiation, apoptosis and growth will be correlated with treatment-associated alterations in redox status of the tumor cells. Currently, the redox state

is defined in relative terms based on the cellular levels of reduced glutathione and MT. Decreased MT expression and lower cellular reduced glutathione levels is expected in tumor cells of animals receiving combination therapy (i.e., butyrate and 5 MESNA and/or DMSA) compared to those untreated or treated with butyrate alone. It is possible that elevated GSH and MT levels from butyrate-induced antioxidant rebound will be observed in the tumors from animals receiving butyrate alone relative to tumors from untreated animals based on our 10 prediction. For this analysis, levels of GSH and MT in tumor cells will be determined flow cytometrically and by Western blot analysis. In addition, an HPLC-based method to quantify cellular levels of oxidized and reduced glutathione will be employed.

2002-09-16 10:50:45

What is Claimed is:

1. A method of maintaining cells in a selected redox state comprising contacting cells with a redox clamping agent which maintains the cells in a selected redox state.

5

2. A method of sensitizing selected cells to a chemotherapeutic agent known to induce a stress response in cells comprising contacting selected cells with a chemotherapeutic agent known to induce a stress response in 10 cells in combination with a redox clamping agent.

3. A method of treating cancer in a patient comprising administering to a patient a chemotherapeutic agent known to induce a stress response in cancer cells in combination with a redox clamping agent.

15

4. A method of inhibiting hyperproliferation of cells comprising contacting cells with a redox clamping agent so that the cells are maintained in a redox state that is not consistent with cell proliferation.

20

5. A method of stabilizing the redox state of cells with abnormal fluctuations in their redox state comprising contacting cells with a redox clamping agent which maintains the cells in a selected redox state.

**Declaration and Power of Attorney For Patent Application**  
2003 03 12 00 00 00  
**English Language Declaration**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the Invention entitled

**Novel Redox Clamping Agents and Uses Thereof**

the specification of which

(check one)

is attached hereto.

was filed on 15 February 2000 as United States Application No. or PCT International Application Number PCT/US00/03878

and was amended on \_\_\_\_\_  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/120,128 (Application Serial No.)	16 February 1999 (Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)



Send Correspondence to:

Direct Telephone Calls to: (name and telephone number)  
Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor <b>Edward J. Yurkow</b>	Sole or first inventor's signature <i>Edward J. Yurkow</i>	Date <b>1/16/02</b>
Residence Hillsborough, New Jersey	<i> NJ</i>	
Citizenship US		
Post Office Address 123 Woods Road		
Hillsborough, New Jersey 08844		

Full name of second inventor, if any <b>Fred H. Mermelstein</b>	Second inventor's signature <i> NJ</i>	Date
Residence Upper Montclair, New Jersey		
Citizenship US		
Post Office Address 64 Dryden Road		
Upper Montclair, New Jersey 07043		

Docket No.  
RU-0130

## Declaration and Power of Attorney For Patent Application

### English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

#### Novel Redox Clamping Agents and Uses Thereof

the specification of which

(check one)

is attached hereto.

was filed on 15 February 2000 as United States Application No. or PCT International

Application Number PCT/US00/03878

and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

#### Prior Foreign Application(s)

Priority Not Claimed

(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/120,128

(Application Serial No.)

16 February 1999

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)



Send Correspondence to:

Direct Telephone Calls to: (name and telephone number)  
Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor <b>Edward J. Yorkow</b>	Date
Signature of first inventor	Date
Residence <b>Hillsborough, New Jersey</b>	
Citizenship <b>US</b>	
Post Office Address <b>123 Woods Road</b>	
<b>Hillsborough, New Jersey 08844</b>	

Full name of second inventor, if any <b>Fred H. Mermelstein</b>	Date
Signature of second inventor <i>Fred H. Mermelstein</i>	Date
Residence <b>Upper Montclair, New Jersey</b>	
Citizenship <b>US</b>	
Post Office Address <b>64 Dryden Road</b>	
<b>Upper Montclair, New Jersey 07043</b>	